The Classic 3 + 3 Design in Dose-finding Clinical Trials and Its Alternatives
Author: Genpro Statistics Team | Date Posted: 28/July/2021 One of the most important goals of Phase 1 clinical trial is to identify the Recommended Phase 2 Dose (RP2D)/Maximum Tolerant Dose (MTD) with acceptable dose-limiting toxicity of the new drug or combination of drugs for the Phase 2 clinical trial, especially in oncology trials. Among all […]
